INTRODUCTION {#S1}
============

Endoplasmic reticulum (ER) stress caused by accumulation of misfolded or unfolded proteins in the ER lumen triggers a multi-faceted program termed unfolded protein response (UPR), which is aimed at restoring ER protein folding capacity ([@R19]; [@R26]; [@R8]). UPR is activated by conformational changes in three major protein sensors, which include membrane-bound transcription factor ATF6 and trans-membrane kinases IRE1α and PERK ([@R9]; [@R10]; [@R19]). Activation of these sensors leads to a decrease in general translation, induction of ER-associated protein degradation (ERAD), and, in parallel, transcriptional induction of multiple genes encoding proteins that promote polypeptide refolding. Transactivation of these genes is achieved by UPR transcription factors that, in addition to ATF6, include ATF4 and XBP1s. ATF4 mRNA is more efficiently translated in response to PERK activation, whereas XBP1 mRNA undergoes removal of a small intron by activated IRE1α, resulting in generation of a spliced variant that encodes a functional form of XBP1 protein, XBP1s ([@R19]; [@R26]; [@R8]). It has been argued that, among the transcription factors induced by UPR, XBP1s is considered the most important for cell survival under ER stress ([@R10]; [@R21]).

On the other hand, prolonged or severe ER stress results in cell death, and elements of UPR have been reported to play an active role in facilitating it ([@R6], [@R7]; [@R5]; [@R4]). The mechanisms underlying the switch from adaptive to cytotoxic (or terminal) UPR are still being investigated.

We have recently discovered that, in the case of oxidative stress, a similar dose-dependent switch from adaptive to cytotoxic response is governed by a rheostat-like mechanism ([@R31]). This mechanism involves the major antioxidant transcription factor (NFE2L2 \[nuclear factor erythroid 2 like 2\] or NRF2; [@R11]), which under conditions of sublethal oxidative stress binds to the regulatory region and transactivates expression of the Krüppel-like factor 9 (KLF9) gene ([@R31]). KLF9 partially represses transcription of genes encoding several antioxidant enzymes, most notably mitochondrial thioredoxin reductase (TXNRD2; [@R1]), leading to additional moderate increase in oxidative stress, which nonetheless is sufficient for causing cell death ([@R31]).

Cell-intrinsic programs governing response to oxidative and ER stresses are among the major pathways regulating cell viability ([@R13]). We therefore hypothesized that a common transcriptional regulatory mechanism exists for oxidative and ER types of stress that transform adaptive stress response into a toxic one when the amounts of stress exceed a certain threshold. To investigate this possibility, we studied the mechanisms of activation of *KLF9* and its downstream programs by ER stress and, intriguingly, identified an NRF2-independent XBP1s-KLF9 axis as a switch controlling a transition from cytoprotective to cytotoxic UPR.

RESULTS {#S2}
=======

KLF9 Is Induced by ER Stress Independently of NRF2 {#S3}
--------------------------------------------------

We have recently demonstrated that a member of the Krüppel-like transcription factor family, KLF9, is upregulated by high doses of oxidative stress. We were interested in whether ER stress activates KLF9 as well. We explored this in several models that are commonly used to study ER stress response: normal human fibroblasts (WI38); human colorectal adenocarcinoma cells (HCT116); mouse embryonic fibroblasts (MEFs); and multiple myeloma cells (MM.1S; [@R18]; [@R25]; [@R17]; [@R24]). The cells were treated with increasing doses of the ER-stress-inducing agents tunicamycin (Tun) or thapsigargin (Tg). Treatment with either agent induced KLF9 mRNA and protein levels in all studied cells (Figures [1A, 1B](#F1){ref-type="fig"}, and [S1A](#SD1){ref-type="supplementary-material"}).

*KLF9* has been identified by us as a direct target of NRF2 ([@R31]). Because NRF2 can be upregulated by Tun or Tg, we depleted NRF2 via 2 independent short hairpin RNAs (shRNAs) in WI38 and HCT116 cells, followed by treatment with Tun or Tg. Depletion of NRF2 did not significantly interfere with upregulation of KLF9 by these agents ([Figures 1C and 1D](#F1){ref-type="fig"}). Similar results were obtained in *Nrf2* knockout MEFs ([Figure S1B](#SD1){ref-type="supplementary-material"}). We concluded that KLF9 is upregulated by ER stress independently of NRF2.

XBP1s Transcriptionally Upregulates KLF9 {#S4}
----------------------------------------

ATF4, ATF6, and XBP1s are the major transcriptional mediators of ER stress response ([@R8]). To identify their role in *KLF9* induction, we individually depleted these proteins via shRNAs in WI38 and HCT116 cells followed by treatment with Tg or Tun and assessment of *KLF9* mRNA levels. ER-stress-dependent KLF9 upregulation was most sensitive to depletion of XBP1s (Figures [2A](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). Similarly, Klf9 levels were lower in Tun-treated *Xbp1* knockout MEFs compared to wild-type MEFs ([Figure 2B](#F2){ref-type="fig"}). Reciprocally, ectopic expression of XBP1s cDNA in WI38 and HCT116 cells induced KLF9 mRNA and protein levels ([Figure 2C](#F2){ref-type="fig"}).

Analysis of regulatory regions of human, mouse, and rat *KLF9* genes identified a single conserved XBP1s binding site in the region corresponding to 5′ UTR of the *KLF9* gene (TGACGTGA). The site fits perfectly the unfolded protein response element (UPREs) consensus (TGACGTG(G/A); [@R27], [@R28]). Accordingly, chromatin immunoprecipitation (ChIP) assay performed in WI38 and HCT116 cells ectopically expressing XBP1s cDNA demonstrated enrichment of DNA fragments containing *KLF9* UPRE in materials precipitated with XBP1s-specific antibodies compared to control (immunoglobulin G \[IgG\]) antibodies ([Figure 2D](#F2){ref-type="fig"}).

To validate the functional importance of the identified UPRE site, we cloned a 471-bp region of the *KLF9* gene containing the wild-type UPRE site into the luciferase reporter pGL3-promoter vector. We also generated a pGL3-promoter vector containing a truncated UPRE site lacking the first 4 bp via site-directed mutagenesis. Empty pGL3-promoter vector or vectors containing wild-type or mutant UPRE were co-transfected into HEK293 cells together with an empty expression vector or a vector expressing XBP1s cDNA. Mutation of the UPRE site completely abrogated XBP1s-induced luciferase expression ([Figure 2E](#F2){ref-type="fig"}). Taken together, these data argue that KLF9 is directly targeted by XBP1s through the conserved UPRE site.

Cytotoxic Levels of ER Stress Induce XBP1S Binding to *KLF9* Promoter {#S5}
---------------------------------------------------------------------

To further evaluate the mechanisms of KLF9 regulation by ER stress, we investigated the KLF9 dose-dependent induction by 24-hr treatment with Tun or Tg in WI38 and HCT116 cells. We noticed that upregulation of *KLF9* mRNA occurred at higher Tun and Tg doses than those required for induction of ER-stress-responsive genes, including several that were previously characterized as XBP1s targets (*SLC30A5*, *RNF19A*, or *RNF121*; Figures [3A--3D](#F3){ref-type="fig"} and [S3A--S3D](#SD1){ref-type="supplementary-material"}). Importantly, KLF9 induction started to occur at doses of Tun and Tg that caused cell death 48 hr post-treatment (Figures [3E, 3F](#F3){ref-type="fig"}, and [S3E](#SD1){ref-type="supplementary-material"}), suggesting that KLF9 is up-regulated by toxic ER stress. To test this hypothesis, we depleted KLF9 via previously characterized shRNAs ([@R31]) in WI38 and HCT116 cells ([Figure 3G](#F3){ref-type="fig"}). These cells in parallel with cells expressing control shRNA were treated with toxic doses of Tun and Tg followed by assessment of cell death. KLF9 depletion substantially decreased cell death, as was evidenced by trypan blue exclusion assay that was also confirmed by annexin V assay (Figures [3H, 3I](#F3){ref-type="fig"}, [S3G, and S3H](#SD1){ref-type="supplementary-material"}; [Table S1](#SD1){ref-type="supplementary-material"}).

Importantly understudied conditions of Tm treatment, levels of reactive oxygen species (ROS) were not significantly upregu lated ([Figure 3J](#F3){ref-type="fig"}). Expression of heme oxygenase 1 (*Hmox1*) gene, a marker of oxidative stress ([@R23]), also remained uninduced ([Figure 3B](#F3){ref-type="fig"}). These data further confirm ROS-independent induction of KLF9 by ER stress.

To investigate mechanisms of dose-dependent regulation of *KLF9* by ER stress, we treated cells with low (0.5 μM) and high (1 μM) amounts of Tun for 24 hr, which resulted in dose-dependent upregulation of XBP1s (Figures [3A](#F3){ref-type="fig"} and [4A](#F4){ref-type="fig"}), followed by ChIP with XBP1s-specific antibodies or control (IgG). The precipitated materials were probed in qPCR with primers flanking the *KLF9* UPRE or the XBP1s binding sites in the regulatory regions of *HSPA5* (*BiP*), *HERPUD1*, *SLC30A5*, *RNF19A*, or *RNF121* ([Figure S4](#SD1){ref-type="supplementary-material"}). XBP1s binding to *KLF9* regulatory regions increased only in cells treated with 1 μM Tun ([Figure 4B](#F4){ref-type="fig"}), whereas an increase in XBP1s binding to promoters of other genes was detected already in cells treated with 0.5 μM Tun ([Figure 4B](#F4){ref-type="fig"}).

We hypothesized that the observed difference could be due to a difference in nucleotide composition of the XBP1s binding sites in promoters of studied genes. From this viewpoint, these genes could be categorized in 2 groups. The first group includes *HSPA5* and *HERPUD1*, which contain more than one XBP1s binding site in their regulatory regions. In addition to the UPRE, these sites include ER stress element I or II (CCAAT(N)~9~CCACG or ATTGG-N-CCACG, respectively; [Figure S4A](#SD1){ref-type="supplementary-material"}). The genes in the second group (*KLF9*, *SLC30A5*, *RNF19A*, or *RNF121*) contain a single UPRE site. It is conceivable that multiple XBP1s-binding elements are likely to interact more efficiently with XBP1s than a single one providing a possible explanation to the data for *HSPA5* and *HERPUD1*. However, regions containing a single UPRE in *SLC30A5*, *RNF19A*, and *RNF121* genes still demonstrate more efficient binding of XBP1s than *KLF9* UPRE ([Figure 4B](#F4){ref-type="fig"}).

Comparison of UPRE sites from the above genes revealed that *KLF9* UPRE differs from the others by a single nucleotide: TGACGTGA versus TGACGTGG ([Figure 4C](#F4){ref-type="fig"}). To determine whether such a difference would affect XBP1s-dependent activation of *KLF9*, we introduced a single (A→G) nucleotide substitution (TGACGTG[A]{.ul} to TGACGTG[G]{.ul}) in the *KLF9* UPRE region in the pGL3-promoter-*KLF9* construct described in [Figure 2E](#F2){ref-type="fig"}. Next, control pGL3-promoter vector and pGL3-promoter vectors containing wild-type or mutant *KLF9* UPRE were transfected into HEK293 cells together with an empty expression vector or a vector expressing XBP1s cDNA, followed by luciferase expression assay. As shown in [Figure 4D](#F4){ref-type="fig"}, a vector containing the A→G mutant UPRE more efficiently upregulated luciferase expression in response to XBP1s overexpression than a vector with wild-type UPRE.

We hypothesized that the A→G mutation would increase XBP1s binding to *KLF9* UPRE. Thus, we compared the ability of wild-type and mutated *KLF9* UPREs to interact with XBP1s in electrophoretic mobility shift assay (EMSA). To this end, 32-bp-long double-stranded DNA fragments (probes) were generated corresponding to *KLF9* regulatory region that contained a wild-type (WT) or an A→G mutant UPRE. First, to determine binding specificity, the WT and mutant probes were incubated with nuclear extracts from wild-type or *Xbp1* knockout MEFs treated with Tun, followed by probing in EMSA. As expected, the *KLF9* UPRE probe interacted with nuclear extracts from wild-type, but not *Xbp1* knockout, MEFs (Figures [4E](#F4){ref-type="fig"} and [S4B](#SD1){ref-type="supplementary-material"}).

Next, equal amounts of wild-type and mutant *KLF9* UPRE probes were individually mixed with a biotin-labeled probe containing a generic UPRE (TGACGTGG) followed by EMSA. In agreement with the luciferase reporter assay data ([Figure 4D](#F4){ref-type="fig"}), the mutant probe was more effective in competing with the generic probe than the wild-type one (Figures [4F](#F4){ref-type="fig"} and [S4B](#SD1){ref-type="supplementary-material"}).

Cumulatively, our data demonstrate that *KLF9* is activated by higher levels of ER stress than other studied XBP1s target genes, most likely due to the nucleotide composition of XBP1s binding site in *KLF9* gene, which requires higher amounts of XBP1s for binding.

KLF9 Causes ER Stress via Upregulation of ER Calcium Release Independently from Induction of Oxidative Stress {#S6}
-------------------------------------------------------------------------------------------------------------

As shown above (Figures [3G](#F3){ref-type="fig"} and [S3G](#SD1){ref-type="supplementary-material"}), KLF9 mediates at least in part cytotoxic effects of Tun or Tg. At the same time, overexpression of KLF9 in studied cells on its own does not induce cell death in the absence of pro-death treatments ([@R31]; data not shown). We have recently reported that KLF9 overexpression moderately increases intracellular ROS via partial transcriptional repression of *TXNRD2* gene ([@R31]). Reciprocally, ectopic expression of TXNRD2 cDNA alleviated oxidative stress induced by KLF9 ([@R31]). Because ROS can promote ER stress, we were interested in whether KLF9 induces ER stress by increasing ROS.

To this end, we generated WI-38 cell populations expressing KLF9 alone or in combination with TXNRD2, as previously described ([@R31]). As was mentioned above, KLF9 overexpression did not cause cell death in the studied cells (data not shown), thus allowing investigation of KLF9-dependent pathways under physiological condition. As expected, ectopic expression of TXNRD2 blunted the ROS increase caused by KLF9 but had only a marginal effect on the induction of ER stress markers ([Figures 5A and 5B](#F5){ref-type="fig"}), suggesting that KLF9 induced ER stress in large part via ROS-independent mechanisms.

To identify KLF9 target genes mediating KLF9-dependent ER stress, we performed global RNA sequencing (RNA-seq) analysis in WI38 cells either overexpressing exogenous KLF9 or depleted of endogenous KLF9 using a previously validated shRNA ([@R31]). We identified 46 genes oppositely regulated by KLF9 overexpression and depletion, out of which 11 genes have been previously shown to participate in ER biogenesis ([Table S2](#SD1){ref-type="supplementary-material"}). Individual analysis of these genes revealed that only 2 of them, transmembrane protein 38B (*TMEM38B*) and inositol 1,4,5-trisphosphate receptor type 1 (*ITPR1*), responded to KLF9 overexpression and interacted with it in ChIP assay ([Table S2](#SD1){ref-type="supplementary-material"}; Figures [5C, 5D](#F5){ref-type="fig"}, and [S5A](#SD1){ref-type="supplementary-material"}). Accordingly, KLF9 depletion decreased levels of *TMEM38B* and *ITPR1* mRNA ([Figure 5E](#F5){ref-type="fig"}). Furthermore, the mRNA levels of both genes were also induced by Tun or Tg at doses that upregulate KLF9 ([Figure 5F](#F5){ref-type="fig"}). ITPR1 and TMEM38B have been previously reported to promote ER calcium release ([@R2]; [@R22]). Moreover, the activity of ITPR1 appears to depend on TMEM38B ([@R22]).

Release of calcium from ER is a critical contributor to cytotoxicity of ER stress. An observation that KLF9 transcriptionally regulates ITPR1 and TMEM38B suggests that KLF9 may be involved in the regulation of calcium levels. To test this directly, we ectopically expressed KLF9 in WI38 cells followed by assessment of cytosolic calcium using the Fluo-4 Direct Calcium Assay Kit (Invitrogen). Intracellular calcium levels were increased by KLF9 overexpression ([Figure 5G](#F5){ref-type="fig"}, left panel). Superinfection with TXNRD2 attenuated KLF9-induced ROS ([Figure 5A](#F5){ref-type="fig"}) but did not affect cytosolic calcium levels in the same cells ([Figure 5G](#F5){ref-type="fig"}, right panel). Accordingly, treatment of KLF9-depleted WI38 cells with Tun resulted in less pronounced transcriptional activation of *TMEM38B* and *ITPR1* ([Figure 5H](#F5){ref-type="fig"}) and lower cytosolic calcium ([Figure 5I](#F5){ref-type="fig"}) when compared to similarly treated control cells.

Importantly, KLF9-dependent increase in intracellular calcium was diminished by shRNA depletion of TMEM38B or ITPR1 ([Figures 5J and 5K](#F5){ref-type="fig"}) without altering KLF9-induced ROS ([Figure S5B](#SD1){ref-type="supplementary-material"}). Furthermore, shRNA-mediated depletion of TMEM38B or ITPR1 decreased the Tun-induced ER stress ([Figure 5L](#F5){ref-type="fig"}) and cell death in WI38 cells ([Figure 5M](#F5){ref-type="fig"}; [Table S3](#SD1){ref-type="supplementary-material"}).

Taken together, our data support the existence of the following axis that underlines the ability of XBP1s to execute a switch from pro-survival to pro-death ER stress response via imposing additional level of ER stress:

above the threshold ER stress→XBP1s→KLF9→TMEM38b+ITPR1→ER calcium release→ER stress→cell death.

Klf9 Deficiency Decreases Tunicamycin-Induced ER Stress in Mouse Liver {#S7}
----------------------------------------------------------------------

To evaluate the role of Klf9 in the induction of the ER stress *in vivo*, we injected Tun or vehicle intraperitoneally into wild-type and *Klf9* knockout 3-month-old mice at a dose of 2 mg/kg, as has been previously described ([@R15]). Mouse liver tissues were collected 30 hr post-injection and analyzed for expression levels of ER stress markers *Edem1* and *Hspa5* using qRT-PCR or for lipid deposition (accumulation of hepatic triglycerides is a hallmark of tunicamycin-induced ER stress in liver) using oil red O staining ([@R29]). Liver tissues from *Klf9* knockout mice treated with Tun had lower levels of ER stress markers (as well as mRNA levels of *Tmem38b* and *Itpr1*; [Figure 6A](#F6){ref-type="fig"}) and decreased lipid deposition compared to livers from wild-type mice ([Figures 6B and 6C](#F6){ref-type="fig"}), thus demonstrating the functional role of Klf9 in control of ER stress *in vivo*.

DISCUSSION {#S8}
==========

ER stress is a condition under which the levels of unfolded proteins exceed the ER's intrinsic folding capacity ([@R19]; [@R26]; [@R8]). ER stress leads to the activation of a well-orchestrated signaling pathway known as the UPR. The goal of the UPR is to restore ER homeostasis via several pathways, including transcriptional activation of genes that increase the ER folding capacity and decrease the cells ability to synthesize new proteins ([@R19]; [@R26]; [@R8]). If these measures fail, the UPR switches from adaptive (cytoprotective) to terminal (cytotoxic) mode ([@R10]; [@R21]).

Although several UPR effectors have been assigned a proapoptotic activity under conditions of prolonged or severe ER stress, including the ATF6→CHOP or PERK→ATF4→CHOP axes, the exact mechanisms explaining dose-dependent switch from adaptive to cytotoxic response have been shown only for very few. For example, high-order IRE1α oligomerization caused by unresolved ER stress increases IRE1a affinity to multiple mRNAs or microRNAs containing IRE1α-dependent decay (RIDD) signals, ultimately resulting in their degradation and apoptosis ([@R6], [@R7]; [@R5]). Similarly, PERK-mediated adaptive ER stress response is countered by PERK-dependent upregulation of pro-apoptotic CHOP protein ([@R8]). It has been shown that, in parallel, PERK can induce expression of miR-211 that attenuates transcriptional activation of CHOP, thus allowing cells to cope with ER stress prior to induction of CHOP-dependent apoptosis ([@R4]).

In the current study, we characterized a principally different mechanism based on transcriptional regulation of the transition from adaptive to terminal UPR by the same transcriptional factor, XBP1s. Interestingly, unlike other UPR transcription factors, such as ATF4, ATF6, or CHOP, XBP1s has not been considered as a mediator of cytotoxic UPR or as an inducer of cell death in general, with very few exceptions ([@R30]; [@R16]). The role of XBP1s in adaptive UPR is usually accounted for by the transcriptional activation of genes encoding ER-resident chaperones ([@R14]), leading to reduction of ER stress and subsequently cell survival.

In the current paper, we demonstrate that, upon increase of ER stress above a certain threshold, elevation in XBP1s amounts leads to its binding to the promoter and transcriptional upregulation of the *KLF9* gene that results in additional calcium release from the ER, aggravation of ER stress, and a proportional increase in cell death. It should be noted, however, that, by itself, overexpression of KLF9 is not toxic to the studied cells ([@R31]). Therefore, KLF9-dependent increase in calcium release under conditions of excessive ER stress only adds to the major pro-apoptotic signaling induced by other branches of terminal ER stress response (e.g., apoptosis induced by transcription factor CHOP; [@R19]).

The sequence of *KLF9* UPRE (TGACGTGA) is conserved among human, mouse, and rat genomes, potentially underlying the evolutionary significance of this basic cellular response to high levels of ER stress. Coincidently, UPREs in other bona fide XBP1s targets containing only one XBP1s binding site differ from *KLF9* UPRE by a single nucleotide (G versus A; TGACGTGG). Our data suggest that the observed differences between *KLF9* and other XBP1s targets with regard to activation by Tun or Tg or XBP1s binding is due to the above-mentioned difference in their UPRE sequences. It is noteworthy that a complementary strand of non-*KLF9* UPREs (CCACGTCA) contains CCACG sequence, which is a part of ER stress elements (ERSEs) I or II (CCAAT(N)~9~CCACG or ATTGG-N-CCACG, respectively). In contrast, the complementary *KLF9* UPRE contains instead TCACG, which is not a part of ERSE sites. The CACCG sequence in ESRE sites binds XBP1s (or ATF6), albeit only if NF-Y factor interacts with another part of ERSE site ([@R27]; [@R12]). It is conceivable that interactions of a canonical UPRE site on one DNA strand with XBP1s may be further increased by the presence of a "conditional" XBP1s binding site (such as CCACG) on a complementary strand.

Our study provides an illustration of how a difference in the affinity of pro-survival and pro-apoptotic targets lets a single transcription factor transform a continuously increasing ER stress signal into qualitatively different outcomes, cell survival, or death.

We have previously reported that *KLF9* is activated by the major antioxidant transcription factor NRF2 when ROS levels exceed a certain threshold. KLF9 induction causes further increase in ROS, ultimately leading to cell death. We demonstrated that this dose-dependent induction was mediated by the exact base pair composition of the antioxidant response element (ARE) in the *KLF9* promoter. Unlike many other NRF2 target genes, the *KLF9* AREs contained no embedded AP-1 consensus sites, which have been shown to increase transcriptional activity of NRF2 ([@R20]; [@R31]). Interestingly, like *KLF9* UPRE, the *KLF9* ARE sequences were also conserved across rodents and human.

Thus, we found it remarkable that a similar dose-dependent mechanism exists for both oxidative and ER stress that is mediated by the nucleotide composition of stress-responsive elements in the regulatory sequences of the same gene, *KLF9*.

Importantly, a two-phase response (first protective and then cytotoxic) is a common scenario for many types of cell stress. Therefore, it is tempting to speculate that the switch to lower affinity targets represents a general paradigm of how a single sensor can drive disparate patterns of cell behaviors in response to quantitative changes in an incoming signal. It remains to be seen how broadly this model is utilized in nature and whether it can account for some of the controversial assignments of both pro-survival and pro-death functions to the same protein. It is worth mentioning that high-throughput annotation of the targets of transcription factors often fails to discriminate between sites with different affinity. Our work suggests that a failure to discern such differences may obscure the molecular basis for fundamentally non-linear behaviors of biological systems.

We demonstrated that KLF9 is capable of inducing ER stress via transcriptional regulation of two genes encoding ER membrane ion channels, TMEM38B and ITPR1. TMEM38B (TRIC-B) was shown to increase intra-ER potassium levels, which promotes calcium release by the ITPR1 calcium channel ([@R2]). Although the role of TMEM38B in cell death is understudied, downregulation of ITPR1 prevented apoptosis ([@R3]), which is in agreement with our findings that individual depletion of ITPR1 decreases Tun-induced expression of ER stress markers and eventually cell death.

We have previously reported that KLF9 overexpression moderately increases intracellular ROSs, which by themselves are not toxic in fibroblasts ([@R31]). Interestingly, suppression of KLF9-dependent ROS via overexpression of TXNRD2 (a direct target of KLF9; [@R31]) in these cells did not significantly reduce levels of KLF9-induced ER stress markers. Reciprocally, depletion of ITPR1 or TMEM38B suppressed KLF9-induced cytoplasmic calcium levels but did not affect KLF9-induced ROS. These observations suggest that, in our experimental conditions, KLF9 induces oxidative stress and ER stress via separate mechanisms. On the other hand, we cannot exclude the possibility that induction of KLF9 by Tun generates KLF9-dependent oxidative stress that also contributes to cell death.

Taken together, our findings help elucidate the molecular mechanisms underlying the transition from adaptive to terminal UPR.

STAR★METHODS {#S9}
============

KEY RESOURCES TABLE {#S10}
-------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                       SOURCE                                                 IDENTIFIER
  --------------------------------------------------------- ------------------------------------------------------ -----------------------------
  Antibodies                                                                                                       

  Anti-KLF9                                                 Santa Cruz Biotechnology                               Sc-12996; RRID:AB_2280771\
                                                                                                                   Sc-12994; RRID:AB_2130595

  Anti-TXNRD2                                               Santa Cruz Biotechnology                               Sc-46279; RRID:AB_2210249

  Anti-ATF4                                                 Santa Cruz Biotechnology                               Sc-200; RRID:AB_2058752

  Anti-β-tubulin                                            Santa Cruz Biotechnology                               Sc-8035; RRID:AB_628408

  Anti-XBP1                                                 Santa Cruz Biotechnology                               Sc-8015; RRID:AB_628449

  Anti-CHOP                                                 Santa Cruz Biotechnology                               Sc-7351; RRID:AB_627411

  Anti-ITPR1                                                Invitrogen                                             PA1-901; RRID:AB_2129984

  Anti-TMEM38B                                              Invitrogen                                             PA5-20859; RRID:AB_11152440

  Anti-ATF6                                                 Novus Biologicals (Littleton, CO; RRID:AB_2058774)     NBP1-40256

  Normal mouse IgG                                          Santa Cruz Biotechnology                               Sc-2025; RRID:AB_737182

  donkey anti-goat IgG-HRP                                  Santa Cruz Biotechnology                               Sc-2020; RRID:AB_631728

  goat anti-mouse IgG-HRP                                   Santa Cruz Biotechnology                               Sc-2005; RRID:AB_631736

  goat anti-rabbit IgG-HRP                                  Santa Cruz Biotechnology                               Sc-2004; RRID:AB_631746

  Chemicals, Peptides, and Recombinant Proteins                                                                    

  Tunicamycin                                               Sigma-Aldrich                                          T7765

  Thapsigargin                                              Sigma-Aldrich                                          T9033

  Protein A/G agarose beads                                 Thermo Fisher                                          \#20421

  Oil-red O stain and fixative                              SclenCell research laboratories                        \#0843a and \#0843b

  DMEM media                                                Invitrogen                                             \#11995-065

  RPMI media                                                Invitrogen                                             \#11875-093

  phosphate buffered saline                                 Invitrogen                                             \#10010-023

  Trypsin-EDTA                                              Invitrogen                                             \#25300-054

  L-glutamine                                               Invitrogen                                             \#25030-081

  HEPES                                                     Invitrogen                                             \#15630-080

  Sodium pyruvate                                           Invitrogen                                             \#11360-070

  Anti Anti                                                 Invitrogen                                             \#15240-062

  Trypan blue stain                                         NutrCyte                                               \#02-0108-0100

  SuperFect reagent                                         QIAGEN                                                 \#301305

  Taqman Universal Master Mix II                            Applied Biosystems                                     \#4440038

  SYBR Green PCR Master Mix                                 Applied Biosystems                                     \#4367659

  CMH2DFCDA                                                 Invitrogen                                             C6827

  Biodyne® B nylon membranes                                Thermo Fisher                                          \#77016

  Critical Commercial Assays                                                                                       

  MycoAlert mycoplasma detection kit                        Lonza                                                  \#LT07-318

  Dual-Luciferase Assay Kit                                 Promega                                                E2920

  subcellular protein fractionation kit                     Thermo Fisher                                          78840

  LightShift Chemiluminescent EMSA Kit                      Thermo Fisher                                          20148

  Chemiluminescent nucleic acid detection module            Thermo Fisher                                          89880

  PureLink® RNA Mini kit                                    Thermo Fisher                                          \#12183025

  cDNA reverse transcription kit                            Invitrogen                                             \#4368814

  Fluo-4 Direct Calcium Assay Kit                           Thermo Fisher                                          F10471

  TruSeq Stranded mRNA kit                                  Illumina                                               \#RS-122-2101

  Deposited Data                                                                                                   

  RNA-seq from WI38 cell populations                        This paper                                             GEO: GSE119427

  Experimental Models: Cell Lines                                                                                  

  HEK293FT                                                  Clonetech                                              \#632180

  MM.1S                                                     American Type Culture Collection                       ATCC® CRL-2974

  WI-38                                                     American Type Culture Collection                       ATCC® CCL-75

  HCT116                                                    American Type Culture Collection                       ATCC® CCL-247

  Nrf2 knockout MEFs                                        Dr. Masayuki Yamamoto (University of Tsukuba, Japan)   N/A

  Xbp1 knockout MEFs                                        Dr. Ann-Hwee Lee (Weill Cornell Medical College)       N/A

  Experimental Models: Organisms/Strains                                                                           

  C57BL/6J                                                                                                         N/A

  KLF9 knockout mice in a C57BL/6J background                                                                      N/A

  Oligonucleotides                                                                                                 

  See [Table S4](#SD1){ref-type="supplementary-material"}                                                          N/A

  Recombinant DNA                                                                                                  

  pCMVdeltaR8.2                                             Addgene                                                \#12263

  pCMV-VSV-G                                                Addgene                                                \#8454

  XBP1s expressing plasmid                                  Genecopoeia (Rockville, MD)                            **EX-Z4299-Lv105-B**

  shRNAs for KLF9                                           Sigma-Aldrich                                          SHCLNG-NM_001206

  shRNAsfor ITPR1                                           Sigma-Aldrich                                          SHCLNG-NM_002222

  shRNAs for TMEM38b                                        Sigma-Aldrich                                          SHCLNG-NM_018112

  shRNAs for XBP1                                           Sigma-Aldrich                                          SHCLNG-NM_005080

  shRNAs for ATF4                                           Sigma-Aldrich                                          SHCLNG-NM_001675

  shRNAs for ATF6                                           Sigma-Aldrich                                          SHCLNG-NM_007348

  pGL3 promoter plasmid                                     Promega                                                \#E1761

  Software and Algorithms                                                                                          

  R statistical software (v. 3.4.2)                                                                                N/A

  DESeq2 workflow103                                                                                               N/A

  QuantStudioTM sequence detection software                 Applied Biosystems                                     N/A
  ----------------------------------------------------------------------------------------------------------------------------------------------

CONTACT FOR REAGENT AND RESOURCE SHARING {#S11}
----------------------------------------

Further information and requests for reagents should be directed to the Lead Contact, Mikhail Nikiforov (<mnikifor@wakehealth.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Mice {#S13}

All experiments involving animals were approved by the institutional Animal Care and Use Committee. All mice were maintained at ambient temperature and humidity and provided food and water *ad libitum*. Pharmacological induction of ER stress in mice was performed according to previous studies ([@R15]). Both males and females mice have been used. 3 month old wild-type mice or KLF9 knockout mice of both on a C57BL/6J background were injected intraperitoneally with TUN (2 μg/gram body weight) or vehicle control (150 μM dextrose). At 30 hours after TUN injection, liver tissue was collected for Oil-red O staining and quantitative real-time PCR analysis. Frozen liver tissue sections were stained with Oil-red O for lipid contents according to standard protocol. Briefly, frozen liver tissue sections of 8-microns were air-dried, and then fixed in formalin. The fixed sections were rinsed in 60% isopropanol followed by staining with freshly prepared Oil-red O solution for 15 min. After Oil-red O staining, liver sections were rinsed in 60% isopropanol and washed with water before being subjected to microscope analysis. All experiments were performed on female mice.

### Cell Cultures {#S14}

HEK293FT were purchased from Clonetech (Mountain View, CA, USA) were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum; human multiple myeloma MM.1S were purchased from American Type Culture Collection (ATCC) were cultured in RPMI (Invitrogen), supplemented with 10% fetal bovine serum, 2mM glutamine, 10mM HEPES pH7.4; non-essential amino acids, 1mM sodium pyruvate and penicillin-streptomycin antibiotics. Human lung fibroblast WI-38 and human colon carcinoma cells HCT116 were purchased from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum. Nrf2 knockout MEFs were obtained from Dr. Masayuki Yamamoto (University of Tsukuba, Japan) and cultured as described previously ([@R31]). Xbp1 knockout MEFs were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 2mM glutamine and penicillin-streptomycin antibiotics. All cell lines were maintained at 37°C with 5% CO~2~. All cell lines have been verified for being mycoplasma-free using MycoAlert mycoplasma detection kit Lonza (Allendale, NJ, USA, Cat \# LT07-318).

### Vectors {#S15}

The pCMVdeltaR8.2 and pCMV-VSV-G vectors were purchased from Addgene (Cambridge, MA, USA). The pLV-SV40-puro lentiviral vector was obtained from Dr. Peter Chumakov, Cleveland Clinic (Cleveland, OH, USA). Human KLF9 or TXNRD2-expressing lentiviral vectors were described previously \[10\]. XBP1s expressing plasmid was purchased from Genecopoeia (Rockville, MD). The pLKO-1 lentiviral vectors containing control shRNA and shRNAs for KLF9, ITPR1, TMEM38b, XBP1, ATF4, and ATF6 were purchased from Sigma-Aldrich. The lentiviral infection protocol has been described previously ([@R31]). Equivalent amounts of control virus were used in all experiments.

### Dual Luciferase Reporter Assay {#S16}

Annealed oligonucleotides containing UPRE sequences were cloned into pGL3 promoter plasmids (Promega) via KpnI and NheI sites, and the inserts were verified by sequencing. The obtained constructs were mixed with pRLSV40 plasmid expressing the Renilla luciferase gene (Promega). WI38 cells were transfected in triplicate with the plasmid mixtures, using SuperFect reagent (QIAGEN). At 48hrs after transfection, firefly luciferase and Renilla luciferase signals were detected via Dual-Luciferase Assay Kit (Promega). Firefly luciferase signals were normalized for the corresponding Renilla luciferase signals.

METHOD DETAILS {#S17}
--------------

### Cell viability assay {#S18}

All cells were collected by trypsinization and an aliquot of cell suspension was mixed 1:1 with Trypan Blue Stain (NutriCyte, Cat no. 02-0108-0100) and incubated at room temperature for 2 minutes. All viable (trypan blue-negative) and nonviable (trypan blue-positive) cells were counted using a hemocytometer under the microscope.

### Immunoblotting {#S19}

Whole cell lysates were prepared and analyzed as previously described (CITE). Membranes were developed using alkaline phosphatase-conjugated secondary antibodies and Pierce Fast Western Blot Kit (Thermo Scientific, Rockford, IL, USA), and the Alpha-Innotech FluorChem HD2 imaging system (Alpha Innotech, San Leandro, CA, USA). For the detection of endogenous KLF9 levels, Pierce SuperSignal West Femto Substrate (Thermo Scientific) was used.

### Electophoretic Mobility Shift Assay (EMSA) {#S20}

Nuclear extracts from tunicamycin treated wild-type or Xbp1−/− MEFs were prepared using the subcellular protein fractionation kit (Thermofisher) according to the manufacturer's recommendations. The extracts were then incubated for 20min at RT with biotin end-labeled oligos containing a single UPRE binding motif as previously described (Yamamoto) and components of the LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific) according to the manufacturer's recommendations. For competition assays, unlabeled probes were used with increasing molarity. The protein/DNA complexes were resolved on 6% native polyacrylamide gels, transferred to Biodyne® B nylon membranes (cat.\# 77016 Thermo Scientific), and UV cross-linked. Membranes were probed using HRP-conjugated streptavidin and exposed to X-ray film for 2--5 minutes before developing. For the list of oligonucleotides, see the Supplemental Experimental Procedures.

### Quantitative Real Time PCR {#S21}

Total RNA was isolated from cells using the PureLinkâ RNA Mini kit (Thermo Fisher Scientific, USA). cDNA was prepared using the cDNA reverse transcription kit (Invitrogen). Quantitative reverse transcription real-time PCR was performed on the QS6 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) using either Taqman Universal Master Mix II (Applied Biosystems) or SYBR Green PCR Master Mix (Applied Biosystems). See [Table S4](#SD1){ref-type="supplementary-material"} for the list of oligonucleotides. PCR data were analyzed using the QuantStudio™ sequence detection software (SDS) (Applied Biosystems).

### Chromatin Immunoprecipitation (ChIP) {#S22}

Interactions between XBP1 and the KLF9, Bip, HERP, SLC30A5, ACC2, and DGAT2 promoters, as well as interactions between KLF9 and the ITPR1 and SLC30A5 promoters were assessed as previously described ([@R31]). The following antibodies from Santa Cruz Biotechnology were used: Xbp1 (sc-7160), KLF9 (sc-12996), and normal mouse IgG (sc-2025). For the list of oligo-nucleotides, see [Table S4](#SD1){ref-type="supplementary-material"}.

### Intracellular calcium measurement {#S23}

Total intracellular calcium was measured using the Fluo-4 Direct Calcium Assay Kit (Thermo Scientific) according to manufacturer's instructions.

### Flow cytometry for reactive oxygen species detection {#S24}

Approximately 3 × 10^5^ cells were collected by trypsinization, washed with phosphate buffered saline and resuspended in 300 μL of Dulbecco's-phosphate buffered saline solution containing 5 μg/ml of CMH2DFCDA (Invitrogen, C6827) according to the manufactures instructions. Cells were incubated at 37°C for 30 min with gentle shaking every 5 min to prevent cells from clumping. Cells were pelleted at 1000rpm for 5 min, washed once with PBS, and resuspended in 0.5 mL DPBS. Fluorescence was measured via flow cytometry (Ex/Em: \~492--495/517--527 nm) using LSRIIA (Becton Dickinson). Detection was based on mean fluorescence intensity of at least 10 000 cells.

### RNA-sequencing {#S25}

Sequencing libraries were prepared with the TruSeq Stranded mRNA kit (Illumina Inc), from 500ng total RNA, following manufacturer's instructions. PCR amplified libraries were pooled in an equimolar fashion, loaded into a 75 cycle NextSeq Reagent cartridge and single-end sequencing performed on a NextSeq500 following the manufacturer's recommended protocol (Illumina Inc.). Genome alignments and feature counting were performed at RPCCC bioinformatics shared resource. Expression count normalization and differential expression were determined using a standard DESeq2 workflow103. Overlaps of DEG lists across comparisons were calculated by hypergeometric testing. All analyses were performed using R statistical software (v. 3.4.2).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

Statistical analyses were performed by Microsoft Excel. All experiments were performed in at least two independent biological replicas. The results are expressed as the average −/+ SEM of the independent experiments. Statistical analysis was performed using Student t test. A two-tailed p value \< 0.05 was considered statistically significant for all analyses.

DATA SOFTWARE AND AVAILABILITY {#S27}
------------------------------

The accession number for the RNA sequencing data obtained in populations of WI38 cells reported in this paper is GEO: GSE119427.
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![KLF9 Is Upregulated by ER Stress Independently from NRF2\
(A and B) Cells were treated with indicated doses of (A) tunicamycin (Tun) or (B) thapsigargin (TG) for 24 hr and probed by qRT-PCR (upper panels, KLF9/β-actin signal ratios are shown) or immunoblotting (lower panels) with indicated antibodies.\
(C) Indicated cells were transduced with control (Cl) or NRF2 (Nsh1 or Nsh2) shRNAs followed by immunoblotting with the indicated antibodies.(D) Cells described in (C) were treated with indicated doses of Tun or TG for 24 hr and probed in qRT-PCR (KLF9/β-actin signal ratios are shown).\
Representative images shown. All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. A p \< 0.05 (\*) was considered significant.](nihms-1509375-f0002){#F1}

![XBP1s Transcriptionally Activates *KLF9*\
(A) Lysates from cells transduced with the indicated shRNAs were probed in immunoblotting with the indicated antibodies (left panels) or treated with indicated doses of Tun followed by qRT-PCR (KLF9/β-actin signal ratios are shown).\
(B) Wild-type or Xbp1 knockout MEFs were probed in qRT-PCR (Klf9/β-actin signal ratios are shown).(C) Cells were transduced with empty vector (V) or XBP1s cDNA followed by immunoblotting with the indicated antibodies or probed in qRT-PCR (KLF9/β-actin signal ratios are shown).(D) DNA from indicated cells was immunoprecipitated with control (IgG) or XBP1s-specific (XBP1s) antibodies. The precipitated material was probed in qPCR with primers for *KLF9* promoter.(E) HEK293FT cells were transfected with the pGL3-promoter-KLF9-WT or pGL3-promoter-KLF9 mutant promoter (lacking first 4 bp of XBP1s UPRE) and the pRLSV40 plasmid expressing the Renilla luciferase gene. Cells were co-transfected with empty vector or XBP1s cDNA. Luciferase activity was measured 24 hr post-treatment.\
Representative images shown. All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. A p \< 0.05 (\*) was considered significant.](nihms-1509375-f0003){#F2}

![*KLF9* Is Upregulated by Toxic Doses of Tunicamycin\
(A--D) Indicated cells treated with the indicated doses of Tun for 24 hr were probed in immunoblotting with the indicated antibodies (A and C) or in qRT-PCR (shown are ratios of signal for an indicated gene and β-actin; B and D).\
(E and F) Viability of cells treated as in (A) or (D) was assessed via trypan blue viability assay.\
(G) Cells transduced with control shRNA (Cl) or KLF9 shRNAs (sh1 and sh2) were probed in immunoblotting with indicated antibodies. Representative images are shown.\
(H and I) Cells described in (G) were treated with Tun for 48 hr and probed in trypan blue viability assay (H) or annexin V apoptosis assay (I).\
(J) Cells were treated with indicated doses of the drugs and analyzed for ROS levels using fluorescence-activated cell sorting (FACS).\
All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. A p \< 0.05 (\*) was considered significant.](nihms-1509375-f0004){#F3}

![XBP1s Does Not Efficiently Interact with the UPRE in *KLF9* Promoter\
(A) Indicated cells treated with the indicated doses of Tun were processed for ChIP assay and immunoprecipitated with IgG or XBP1s-specific antibodies followed by immunoblotting with XBP1s antibodies.\
(B) Cells treated as in (A) were probed by qPCR with primers encompassing XBP1s binding sites in the regulatory regions of indicated genes (see [Figure S4A](#SD1){ref-type="supplementary-material"}).\
(C) Nucleotide sequence of the UPRE sites in the regulatory regions of indicated genes.\
(D) HEK293FT cells were transduced with the pGL3-promoter-KLF9-WT or pGL3-promoter-KLF9 mutant promoter (containing TGACGTGG sequence) and the pRLSV40 plasmid expressing the Renilla luciferase gene. Cells were co-transfected with empty vector or XBP1s cDNA. Luciferase activity was measured 24 hr post-treatment.\
(E) Nuclear extracts from tunicamycin-treated wild-type and Xbp1s−/− MEFs were incubated with biotin-labeled probe containing wild-type (wt) or mutant (mut) *KLF9* UPRE and resolved on native gels. Protein/DNA complexes were visualized with a chemiluminescent system.\
(F) Nuclear extracts from tunicamycin-treated wild-type MEFs were incubated with a biotin-labeled probe containing a generic UPRE site and increasing amounts of unlabeled wt or mut *KLF9* UPRE. Protein/DNA complexes were visualized with a chemiluminescent system.\
Representative images shown. All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. A p \< 0.05 (\*) was considered significant.](nihms-1509375-f0005){#F4}

![KLF9 Increases Intracellular Calcium Levels\
All experiments were performed in WI38 cells.\
(A) Cells expressing the indicated constructs were analyzed for ROS levels using FACS.\
(B) Cells described in (A) were probed in qRT-PCR with the indicated probes (shown are ratios of signal for an indicated gene and β-actin).\
(C) Cells transduced with V or KLF9 cDNA (KLF9) were probed in immunoblotting with indicated antibodies (left panel) or in qRT-PCR with the indicated probes (right panel; shown are ratios of signal for an indicated gene and β-actin).\
(D) DNA from cells overexpressing KLF9 cDNA was immunoprecipitated with control (IgG) or KLF9-specific (KLF9) antibodies. The precipitated material was probed in qPCR with primers for *TMEM38B* or *ITPR1* promoters.\
(E) Cells transduced with control shRNA (Cl) or KLF9 shRNAs (sh1 and sh2) were probed in immunoblotting with indicated antibodies (left panel) or in qRT-PCR with the indicated probes (right panel; shown are ratios of signal for the indicated gene and β-actin).\
(F) Cells were treated with indicated doses of Tun for 24 hr followed by qRT-PCR with the indicated probes (shown are ratios of signals for an indicated gene and β-actin).\
(G) Cells expressing empty vector, KLF9 cDNA, TXNRD2 cDNA, or co-expressing these constructs (as in A) were probed for intracellular calcium content using Fluo-4 Direct Calcium Assay Kit.\
(H) Control and KLF9-depleted cells (described in E) were treated with indicated doses of Tun for 24 hr followed by qRT-PCR with the indicated probes (shown are signal ratios for an indicated gene and β-actin).\
(I) Cells described in (H) were probed for intracellular calcium content using Fluo-4 Direct Calcium Assay kit.\
(J) Cells were transduced with the control shRNA (Cl) or ITPR1 shRNAs (ITsh1 and ITsh5) or TMEM38B shRNAs (TMsh1 and TMsh3) followed by immunoblotting with indicated antibodies.\
(K) Cells expressing indicated constructs were probed for intracellular calcium content using Fluo-4 Direct Calcium Assay Kit.\
(L) Cells expressing indicated constructs were probed in qRT-PCR with the indicated probes (shown are ratios of signal for an indicated gene and β-actin).\
(M) Cells described in (K) were treated with indicated doses of Tun for 48 hr and analyzed by trypan blue viability assay.\
Representative images shown. All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. A p \< 0.05 (\*) was considered significant.](nihms-1509375-f0006){#F5}

![Klf9 Deficiency Decreases ER Stress Markers and Hepatic Steatosis in Mice\
(A) WT and *Klf9* knockout mice (KO) mice were injected intraperitoneally with vehicle (V) or Tun. The animals were euthanized, and the livers were excised 30 hr post-injection. RNA isolation and expression of the indicated genes was assayed by qRT-PCR (shown are ratios of signal for an indicated gene and β-actin).\
(B) Sections of livers from mice described in (A) were fixed in formalin and stained with oil red O.\
(C) Quantification of oil red drops in samples described in (B).\
Representative images shown. All data represent mean ± SEM of 2 or more biological replicates. Statistical significance was analyzed using two-tailed Student's t test. \*p \< 0.05; \*\*p \< 0.01. A p \< 0.05 was considered significant.](nihms-1509375-f0007){#F6}

###### Highlights

-   XBP1s transcriptionally activates *KLF9* under conditions of high ER stress

-   KLF9 transcriptionally activates *TMEM38B* and ITPR1 to control ER calcium release

-   KLF9 further increases ER stress via facilitating calcium release from ER

-   Klf9 deficiency reduces tunicamycin-induced ER stress in mouse liver
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